Premium
Digital Therapeutics: An Integral Component of Digital Innovation in Drug Development
Author(s) -
Sverdlov Oleksandr,
van Dam Joris,
Hannesdottir Kristin,
ThorntonWells Tricia
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1036
Subject(s) - modalities , drug development , digital health , modality (human–computer interaction) , psychological intervention , component (thermodynamics) , business model , medicine , therapeutic modalities , risk analysis (engineering) , business , computer science , drug , health care , pharmacology , marketing , human–computer interaction , political science , social science , physics , sociology , law , thermodynamics , physical therapy , psychiatry
Digital therapeutics represent a new treatment modality in which digital systems such as smartphone apps are used as regulatory‐approved, prescribed therapeutic interventions to treat medical conditions. In this article we provide a critical overview of the rationale for investing in such novel modalities, including the unmet medical needs addressed by digital therapeutics and the potential for reducing current costs of medical care. We also discuss emerging pathways to regulatory approval and how innovative business models are enabling further growth in the development of digital therapeutics. We conclude by providing some recent examples of digital therapeutics that have gained regulatory approval and highlight opportunities for the near future.